United Therapeutics Co. (NASDAQ:UTHR) Shares Acquired by Alliancebernstein L.P.

Alliancebernstein L.P. boosted its holdings in United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 28.5% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 709,043 shares of the biotechnology company's stock after purchasing an additional 157,363 shares during the quarter. Alliancebernstein L.P. owned approximately 1.59% of United Therapeutics worth $250,179,000 as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in the stock. Newbridge Financial Services Group Inc. bought a new position in shares of United Therapeutics during the fourth quarter worth $25,000. Millstone Evans Group LLC bought a new position in shares of United Therapeutics during the 4th quarter valued at about $67,000. MassMutual Private Wealth & Trust FSB grew its position in shares of United Therapeutics by 31.9% during the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 240 shares of the biotechnology company's stock valued at $85,000 after purchasing an additional 58 shares in the last quarter. Jones Financial Companies Lllp increased its holdings in shares of United Therapeutics by 678.9% in the fourth quarter. Jones Financial Companies Lllp now owns 296 shares of the biotechnology company's stock worth $104,000 after purchasing an additional 258 shares during the last quarter. Finally, SBI Securities Co. Ltd. purchased a new stake in shares of United Therapeutics in the fourth quarter worth about $131,000. 94.08% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at United Therapeutics

In other United Therapeutics news, COO Michael Benkowitz sold 10,000 shares of the stock in a transaction that occurred on Tuesday, January 21st. The shares were sold at an average price of $364.91, for a total value of $3,649,100.00. Following the sale, the chief operating officer now directly owns 2,577 shares of the company's stock, valued at approximately $940,373.07. This represents a 79.51 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, Director Tommy G. Thompson sold 2,500 shares of the business's stock in a transaction on Monday, March 24th. The stock was sold at an average price of $318.80, for a total transaction of $797,000.00. Following the transaction, the director now owns 8,480 shares of the company's stock, valued at approximately $2,703,424. The trade was a 22.77 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 72,500 shares of company stock worth $26,134,500 over the last three months. Insiders own 11.90% of the company's stock.

Remove Ads

United Therapeutics Trading Up 1.8 %

UTHR traded up $5.38 on Wednesday, hitting $312.26. 461,017 shares of the company's stock were exchanged, compared to its average volume of 450,237. The firm has a 50-day moving average price of $336.64 and a 200-day moving average price of $355.09. The stock has a market cap of $14.02 billion, a price-to-earnings ratio of 13.71, a P/E/G ratio of 0.97 and a beta of 0.64. United Therapeutics Co. has a fifty-two week low of $227.75 and a fifty-two week high of $417.82.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last announced its quarterly earnings results on Wednesday, February 26th. The biotechnology company reported $6.19 earnings per share for the quarter, beating the consensus estimate of $6.10 by $0.09. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. The firm had revenue of $735.90 million for the quarter, compared to analysts' expectations of $734.74 million. During the same quarter in the previous year, the company posted $4.36 EPS. On average, equities analysts predict that United Therapeutics Co. will post 24.48 EPS for the current year.

Wall Street Analysts Forecast Growth

Several equities analysts have weighed in on UTHR shares. UBS Group lifted their price objective on United Therapeutics from $415.00 to $475.00 and gave the stock a "buy" rating in a research note on Wednesday, January 8th. StockNews.com lowered shares of United Therapeutics from a "strong-buy" rating to a "buy" rating in a report on Thursday, February 27th. Finally, HC Wainwright reaffirmed a "buy" rating and set a $425.00 price target on shares of United Therapeutics in a research note on Thursday, February 27th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and ten have given a buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $388.25.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.